Stanford engineers invent process to accelerate protein evolution
12/08/2015
All living things require proteins, members of a vast family of molecules that nature "makes to order" according to the blueprints in DNA.
RVG-exosome delivered MOR-RNAi rescues drug addiction
12/08/2015
MiRNAs are a class of naturally occurring small non-coding RNAs that have been linked to biological possesses and diseases development.
New technology may standardize sickle cell disease screening for infants
12/08/2015
Researchers from Seidman Cancer Center at University Hospitals Case Medical Center and Case Western Reserve University School of Medicine presented new research findings at the 57th Annual Meeting of...
Cancer study identifies genes that stop onset of leukemia
12/08/2015
Genes that act as brakes to stop the development of an aggressive form of leukaemia have been identified by researchers.
High response rates, long-term remissions in Penn trials of personalized cell therapy
12/08/2015
Ninety-three percent of pediatric patients (55 of 59) with relapsed/refractory acute lymphoblastic leukemia (ALL) went into remission after receiving an investigational therapy made from their own...
New guideline addresses long-term needs of breast cancer survivors
12/08/2015
A new breast cancer survivorship care guideline created by the American Cancer Society and the American Society of Clinical Oncology provides guidance to primary care and other clinicians in caring...
Stroke risk for older men who take alpha-blockers
12/07/2015
New research finds that older men who take alpha-blockers - typically used to treat high blood pressure and improve urine flow - are at increased risk for stroke.
Adaptive Biotechnologies and its collaborators have presented data at the American Society of Hematology (ASH) Annual Meeting showing that the clonoSEQ® minimal residual disease (MRD) Test can...
ADC Therapeutics SA, the oncology drug development company focused on Antibody Drug Conjugates (ADCs), today announced that it has received clearance from the US Food and Drug Administration (FDA)...
Lymphoma: 67% complete response shown in Phase 1 BelCHOP study
12/07/2015
Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations and a primary focus in Hematology and Oncology, and Onxeo S.A.